Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005044 · ClinicalTrials.gov registry record · Phase 3
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,579
- Enrollment target
NCT00005044 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,579 participants.
The verdict
NCT00005044, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,579 participants
- Enrollment target
Study Summary
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of hormone therapy and radiation therapy in treating patients who have prostate cancer.
Interventions
- DRUG LHRH agonist
- RADIATION radiation therapy
- DRUG Casodex
- DRUG Eulexin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,579 participants |
| Start Date | 2000-02 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005044
The ClinicalTrials.gov registry entry for NCT00005044 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,579 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LHRH agonist is the first listed.
NCT00005044 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005044 about?
NCT00005044 is a clinical study titled "Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of hormone therapy and radiation therapy is mor...
What is the current status of trial NCT00005044?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,579 participants. The study started on 2000-02. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT00005044?
The interventions under investigation include: LHRH agonist (DRUG), radiation therapy (RADIATION), Casodex (DRUG), Eulexin (DRUG).
Who is sponsoring clinical trial NCT00005044?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.